Showing 8651-8660 of 9458 results for "".
- MRF to UPSTF: Reconsider Supporting Annual Skin Cancer Checkshttps://practicaldermatology.com/news/mrf-to-upstf-reconsider-support-for-annual-skin-cancer-checks/2458479/The Melanoma Research Foundation (MRF) is urging the U.S. Preventive Services Task Force’s (USPSTF) to reconsider their recent announcement stating that insufficient data exists to support a recommendation for annual skin canc
- Study: 98% of Head Lice in at Least 42 States Now Resistant to Common OTC Treatmentshttps://practicaldermatology.com/news/98-of-head-lice-in-at-least-42-states-now-resistant-to-common-otc-treatments/2458480/Fully 98 percent of head lice in at least 42 states are resistant to various over-the-counter pyrethrins and pyrethroids including permethrin, which is the active ingredient in popular treatment formulations for pediculosis (Nix® (permethrin 1%), according to a study in t
- ASDS Disagrees with New Skin Cancer Screening Recommendationhttps://practicaldermatology.com/news/asds-disagrees-with-new-skin-cancer-screening-recommendation/2458483/The US Preventive Service Task Force (USPSTF) has declined to take a stance on the value of preventive skin cancer screenings for the second time in seven years, and The American Society for Dermatologic Surgery ASDS is responding with disappointment. The USPSTF says there is insufficient
- Dermatologist Todd Schlesinger to Host Bellafill Discussion Fridayhttps://practicaldermatology.com/news/dermatologist-todd-schlesinger-to-host-bellafill-discussion-friday/2458484/Todd E. Schlesinger, MD, FAAD will host a program on behalf of Suneva, in which he will discuss Suneva's Bellafill® and other products. The event will be held Friday, July 29th, 2016 at 8pm at Towne Stove and Spirits, 900 Boylston Street, Boston. Those interested in atte
- Study: Sleeping It Off Is No Wrinkle Curehttps://practicaldermatology.com/news/study-sleeping-it-off-is-no-wrinkle-cure/2458486/Stomach and side sleeping positions cause wrinkles over time, and the effect is worsened with advancing age, new research suggests. The findings are published in Aesthetic Surgery Journal.<
- Galderma and Chugai Announce Global License Agreement for Nemolizumab, Novel Biologic for Skin Diseaseshttps://practicaldermatology.com/news/galderma-and-chugai-announce-global-license-agreement-for-nemolizumab-novel-biologic-for-skin-diseases/2458496/Chugai Pharmaceutical Co., Ltd. and Galderma Pharma S.A. have entered into a global license agreement for nemolizumab (CIM331), the anti-IL-31 receptor A humanized monoclonal antibody created by Chugai, which is currently under development for atopic dermatitis and pruritus in hemodialysis patien
- Is 'Mitoiron Claw' the Next Great Sunscreen Ingredient?https://practicaldermatology.com/news/is-mitoiron-claw-the-next-great-sunscreen-ingredient/2458493/A new compound that blocks excess free iron in the mitochondria may offer dramatic protection against Ultraviolet A (UVA) radiation in sunlight, according to scientists at the University of Bath and King's College London. Most sunscreens protect well against solar Ultraviolet B
- ASDS: Interest in Cosmetic Surgery On the Risehttps://practicaldermatology.com/news/asds-interest-in-cosmetic-surgery-on-the-rise/2458498/Nearly six in 10 individuals are considering a cosmetic medical procedure today, up 50 percent since 2013, according to the annual American Society for Dermatologic Surgery (ASDS) Consumer Survey on Cosmetic Dermatologic Procedur
- ISDIN Launches in the UShttps://practicaldermatology.com/news/isdin-launches-in-the-us/2458501/Barcelona-based ISDIN is officially operating in the US. The company—which operates in Europe, Latin America, and Asia—is bringing its skincare products to the US market. ISDIN’s portfolio of over-the-counter products target
- FDA Advisory Committee Votes to Approve Biosimilar Etanercept from Sandozhttps://practicaldermatology.com/news/fda-advisory-committee-votes-to-approve-biosimilar-etanercept-from-sandoz/2458502/The US FDA Arthritis Advisory Committee recommended approval of Sandoz's proposed biosimilar etanercept. The committee voted unanimously (20-0), in support of biosimilar etanercept for all five indications of the reference product, including rheumatoid arthritis (RA), plaque psoriasis (PsO),